For example, in precision medicine for selection for type 2 diabetes, a large patient group better suited for SGLT2 inhibitor therapy was under-recommended for it due to low overall cardiorenal disease risk, with only 14.3% receiving the suggestion. Here, SLC5A2 is linked to type 2 diabetes mellitus.